Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition charges clouding the quarter, here is where the stock heads next. The 24/7 ...

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock ...

Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges.

Okay, I thought Merck got, you know what, Merck reported a really good quarter, and it just happened on a day when people ...

Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...

Janux Therapeutics, Inc. upgraded to Strong Buy: below cash value, strong runway, TRACTr progress, Merck/BMY milestones.

Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and ...

Merck has faced some challenges in recent years, as its HPV vaccines, Gardasil and Gardasil 9, have seen declining sales due to issues in Asia. Further, Merck may face increased competition in the ...

Merck’s widely used immunotherapy, Keytruda, drove the company’s topline growth during the quarter, accounting for nearly ...

Shares of Merck & Co. Inc. MRK shed 2.07% to $115.46 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.26% to 7,041.28 and ...